BR112022021992A2 - Método de tratamento de câncer em um sujeito em necessidade do mesmo - Google Patents

Método de tratamento de câncer em um sujeito em necessidade do mesmo

Info

Publication number
BR112022021992A2
BR112022021992A2 BR112022021992A BR112022021992A BR112022021992A2 BR 112022021992 A2 BR112022021992 A2 BR 112022021992A2 BR 112022021992 A BR112022021992 A BR 112022021992A BR 112022021992 A BR112022021992 A BR 112022021992A BR 112022021992 A2 BR112022021992 A2 BR 112022021992A2
Authority
BR
Brazil
Prior art keywords
sirpa
treatment
cancer
subject
need
Prior art date
Application number
BR112022021992A
Other languages
English (en)
Inventor
Puro Robyn
Hiebsch Ronald
Capoccia Benjamin
Andrejeva Gabriela
Sousa Pereira Daniel
Original Assignee
Arch Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Oncology Inc filed Critical Arch Oncology Inc
Publication of BR112022021992A2 publication Critical patent/BR112022021992A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO DE TRATAMENTO DE CÂNCER EM UM SUJEITO EM NECESSIDADE DO MESMO. Trata-se de anticorpos monoclonais anti-SIRPa (mAbs anti-SIRPa), incluindo anticorpos SIRPa multiespecíficos, que são dotados de perfis funcionais distintos, assim como composições relacionadas e métodos de uso de mAbs anti-SIRPa como produtos terapêuticos para a prevenção e tratamento de cânceres sólidos e hematológicos. Também são fornecidas sequências de aminoácidos de anticorpos monoclonais anti-SIRPa exemplificativos.
BR112022021992A 2020-04-30 2021-04-30 Método de tratamento de câncer em um sujeito em necessidade do mesmo BR112022021992A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063018177P 2020-04-30 2020-04-30
US202063071732P 2020-08-28 2020-08-28
US202063107200P 2020-10-29 2020-10-29
PCT/US2021/030163 WO2021222746A2 (en) 2020-04-30 2021-04-30 THERAPEUTIC SIRPα ANTIBODIES

Publications (1)

Publication Number Publication Date
BR112022021992A2 true BR112022021992A2 (pt) 2023-01-03

Family

ID=78373977

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021992A BR112022021992A2 (pt) 2020-04-30 2021-04-30 Método de tratamento de câncer em um sujeito em necessidade do mesmo

Country Status (6)

Country Link
US (1) US20230279108A1 (pt)
JP (1) JP2023524238A (pt)
CN (1) CN116234572A (pt)
AU (1) AU2021264006A1 (pt)
BR (1) BR112022021992A2 (pt)
WO (1) WO2021222746A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
EP4687990A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024025A1 (en) * 2003-09-11 2005-03-17 Ecopia Biosciences Inc. Polyene polyketides and methods of production
ATE543835T1 (de) * 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
DK2804878T3 (en) * 2012-01-20 2018-12-17 Genzyme Corp ANTI-CXCR3 ANTIBODIES
MX2019009255A (es) * 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
BR112020016049A2 (pt) * 2018-03-09 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anti-cd73 e seus usos

Also Published As

Publication number Publication date
WO2021222746A3 (en) 2022-01-20
CN116234572A (zh) 2023-06-06
WO2021222746A2 (en) 2021-11-04
AU2021264006A1 (en) 2022-12-01
JP2023524238A (ja) 2023-06-09
US20230279108A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2022003930A (es) Conjugados de péptido de camptotecina.
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2016077734A3 (en) Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
BR112018011029A2 (pt) métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
PH12018500520A1 (en) Cd3 binding polypeptides
WO2021222746A3 (en) THERAPEUTIC SIRPα ANTIBODIES
BR112022005114A2 (pt) Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
BR112018068702A2 (pt) inibidores bicíclicos em ponte de menin-mll e métodos de uso
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
GEP20125517B (en) Humanized monoclonical antibodies to hepatocyte growth factor
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
MX386680B (es) Polimorfo de macrociclo de diarilo.
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
BR112022000876A2 (pt) Anticorpos imunomoduladores e métodos de uso destes
BR112022008552A2 (pt) Moléculas de ligação multiespecíficas de scfv de terminal-n
BR112018006140A2 (pt) anticorpo ou uma porção de ligação a antígeno do mesmo, composição farmacêutica, e, método para inibição de proliferação de células cancerígenas.
BR112017018778A2 (pt) conjugados anticorpo-fármaco à base de criptoficina com ligantes autodegradantes inovadores
MX2021013850A (es) Anticuerpo contra tigit y uso del mismo.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ARCH ONCOLOGY, INC. (US)

B10A Cessation: cessation confirmed